Biologic Imaging Reagents: Technologies and Global Markets

December 18, 2008

Wellesley, Mass—According to a new technical market research report, BIOLOGIC IMAGING REAGENTS: TECHNOLOGIES AND GLOBAL MARKETS (BIO064A) from BCC Research, the global market for biologic imaging reagent technology is expected to be worth $5.8 billion in 2008. This will increase to over $9.5 billion in 2013, for a compound annual growth rate (CAGR) of 10.2%.

The market is broken down into contrast reagents, optical reagents and nuclear reagents. Of these, contrast reagents have the largest share of the market, worth an estimated $2.6 billion in 2008. This should increase to $3.7 billion in 2013, for a CAGR of 7.2%.

Nuclear reagents have the second largest market share, generating an estimated $2.1 billion in 2008. This is expected to increase at a CAGR of 12.5% to reach $3.7 billion in 2013.

The third largest share of the market belongs to optical reagents, with sales of over $1.2 billion in 2008. This should reach $2.1 billion in 2013, for a CAGR of 12.1%.

To Contact us, click here  

Biologic imaging reagents play a fundamental role in today’s medical, pharmaceutical and biotechnology industries. Optical imaging reagents allow life sciences researchers and drug developers to visualize and detect biological processes at the molecular level and to perform key genomics, proteomics and cellular analysis assays. Nuclear and contrast reagents provide important diagnostic information to physicians, enabling the early detection and treatment of disease conditions in cardiology, neurology and oncology.

Technology and market forces are creating a key shift in biologic imaging reagents toward highly specific, multifunctional reagents. This shift is creating opportunities for reagent manufacturers to address strategic market opportunities in genomics, proteomics, live cell imaging, early detection of cancers and neurological disorders, drug development, and hybrid imaging/therapeutic reagents. 

A main competitive strategy for achieving success in biologic imaging reagents businesses has been acquiring unique technology in fluorescent proteins, fluorescence dyes and probes, quantum dots, and nanotechnology. A second route to gaining technological competitive advantage is through strategic industry alliances.
 

Biologic Imaging Reagents: Technologies and Global Markets( BIO064A )
Publish Date: Jan 2009    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.